Protocol Overview
Synergy & Mechanism
BPC-157 Mechanism
BPC-157 is a pentadecapeptide derived from human gastric juice that promotes tissue healing through angiogenesis (new blood vessel formation), upregulation of VEGF, EGF, and FGF growth factors, and nitric oxide modulation. It creates the vascular infrastructure needed to deliver nutrients and building materials to damaged tissue.
GHK-Cu Synergy
GHK-Cu is a copper-binding tripeptide that naturally declines with age. It stimulates collagen I, III, and V synthesis, elastin production, and glycosaminoglycan formation. While BPC-157 builds the vascular highway, GHK-Cu provides the structural materials for tissue remodeling. GHK-Cu also attracts stem cells and reduces oxidative damage at repair sites.
Combined Dosing Protocol
Standard
BPC-157 250mcg/day SubQ
GHK-Cu 200mcg/day SubQ
AM
6-8 weeks
Enhanced
BPC-157 500mcg/day SubQ
GHK-Cu 400mcg/day SubQ
AM + PM split
8-12 weeks
Topical Combo
GHK-Cu cream 2x/day topical
AM + PM
8 weeks
Reconstitution & Preparation
BPC-157 Preparation
BPC-157 vial: typically 5mg lyophilized
Reconstitute with 2mL BAC water = 2,500mcg/mL
250mcg dose = 10 units on insulin syringe
Refrigerate, use within 30 days
GHK-Cu Preparation
GHK-Cu vial: typically 50mg lyophilized
Reconstitute with 2mL BAC water = 25mg/mL
200mcg dose = 0.8 units on insulin syringe
Also available as topical cream (0.1-1%)
Stacking Schedule (AM/PM Timing)
AM Protocol
Morning: BPC-157 250mcg SubQ near target area
Morning: GHK-Cu 200mcg SubQ (same area or facial)
Inject sequentially at slightly different sites
Do not mix in same syringe
PM Protocol (Enhanced)
Evening: GHK-Cu topical cream to target skin
Or second SubQ dose of GHK-Cu 200mcg
BPC-157 can be split AM/PM for aggressive protocols
Consistent daily dosing is key
Expected Timeline
Side Effects & Monitoring
Common Side Effects
Injection site redness (mild, transient)
Mild dizziness (uncommon)
Skin flushing at GHK-Cu injection site
Metallic taste (GHK-Cu, rare)
Both compounds have excellent safety profiles with minimal adverse effects at standard doses.
Precautions
GHK-Cu contains copper - avoid in Wilson's disease
May promote angiogenesis in tumors (theoretical)
Avoid if active cancer or cancer history
Limited human clinical trial data for injectable GHK-Cu
Blood Work Recommendations
Inflammatory
CRP, ESR
Baseline, Week 4, Week 8
Basic
CBC, CMP
Baseline, Week 6
Copper
Serum copper, ceruloplasmin
Baseline, Week 6 (if concerned)
Monitor inflammatory markers to track healing. Check copper levels if using high-dose GHK-Cu for extended periods.
Related Protocols & Tools